Americans now say they approve of free trade by 64%-27%, a margin of better than two to one. That's up from 57%-37% early in Trump's presidency, and 51%-41% near the end of...Politicsread more
The yield on the benchmark 10-year Treasury note briefly fell below the 2-year rate on Wednesday, a phenomenon in the bond market known as yield curve inversion, which is...Marketsread more
The MacBook Pro recall and its subsequent ban from flights underscores the increasing brand risk from problems with lithium-ion batteries.Technologyread more
Experts say the timing of Amazon executives' contributions to Rep. David Cicilline likely reflect the company's heightened urgency over growing regulatory scrutiny.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Coinbase security chief Philip Martin explains, "Possession of a key is possession of your currency. What that means is that you can't revoke a cryptocurrency key, if that key...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
The Supreme Court could strike down the constitutionality of the Consumer Financial Protection Bureau, an agency Elizabeth Warren has likened to her child and which Justice...2020 Electionsread more
Bianco Research's James Bianco suggests Wall Street is desperately looking for a signal that a 50 basis point cut is coming next month.Trading Nationread more
The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
Inovio Pharmaceuticals' Zika vaccine will be the 14th drug the company has in testing, but its CEO insisted Tuesday the company is not spread too thin and is ready to take on its larger rivals.
Inovio announced Monday its experimental vaccine for the Zika virus received approval from U.S. regulators for an early-stage human trial testing.
"Our pipeline is very full and very productive. We're able to advance a lot of products," president and CEO Joseph Kim said in an interview with "Power Lunch " on Tuesday. "We can rapidly and safely move these programs forward."
The early-stage Zika study will enroll 40 healthy subjects and evaluate safety, tolerability and immune response to the vaccine.
The World Health Organization declared Zika a global health emergency. The illness has been associated with microcephaly, a birth defect characterized by an usually small head and potential developmental problems.
Inovio also has an Ebola vaccine in the pipeline and is competing against the likes of Merck, Johnson & Johnson and GlaxoSmithKline. However, Kim is confident his company can take on its larger rivals.
"We're fortunate enough to have a technology and DNA-based therapies where we can safely and perhaps more efficiently and effectively advance these products," he said.
Meanwhile, its "leading product" for cervical dysplasia is about to enter phase-three studies, said Kim. He downplayed the two-year gap between the drug's phase-two and phase-three studies.
"It takes a long time to take new disruptive technologies for these important diseases forward," he explained.
— Reuters contributed to this report.